Small Cell Lung Cancer Recurrent Clinical Trial
Official title:
Study of Irinotecan Liposome Combined With Anlotinib as Second-line Regimen in Patients With Small Cell Lung Cancer
This study is a single arm, multi-center, prospective clinical trial. The purpose of this study is to evaluate the efficacy and safety of liposomal irinotecan combined with anlotinib hydrochloride for relapsed small-cell lung cancer, who have progressed on or less than 6 month after platinum-based first-line therapy.
Patients will receive irinotecan liposome injection at 70 mg/m^2 intravenously, on Days 1 of every 14-day cycle and anlotinib (12 mg/day) for 2 consecutive weeks and then discontinued for 1 week. The treatment is continued until disease progression or intolerable toxicity. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05815160 -
Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
|
Phase 1 | |
| Completed |
NCT03823118 -
S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT03262454 -
Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC
|
Phase 2 | |
| Terminated |
NCT02477813 -
Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT Methylation
|
Phase 2 | |
| Terminated |
NCT05027867 -
KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT01441297 -
BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT03994744 -
Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC
|
Phase 2 |